NYSE:IQV - IQVIA Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$102.26 +0.63 (+0.62 %)
(As of 05/21/2018 02:26 PM ET)
Previous Close$101.52
Today's Range$101.31 - $103.37
52-Week Range$82.83 - $110.67
Volume51,840 shs
Average Volume1.19 million shs
Market Capitalization$21.05 billion
P/E Ratio23.40
Dividend YieldN/A
Beta0.64

About IQVIA (NYSE:IQV)

IQVIA logoIQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Integrated Engagement Services segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company serves pharmaceutical, biotechnology, device and diagnostic, and healthcare companies. IQVIA Holdings Inc. has a strategic alliance with MuleSoft, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Receive IQV News and Ratings via Email

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
SymbolNYSE:IQV
CUSIPN/A
Phone203-448-4600

Debt

Debt-to-Equity Ratio1.22
Current Ratio1.16
Quick Ratio1.16

Price-To-Earnings

Trailing P/E Ratio23.40
Forward P/E Ratio20.21
P/E Growth1.7

Sales & Book Value

Annual Sales$9.74 billion
Price / Sales2.17
Cash Flow$9.8327 per share
Price / Cash10.40
Book Value$40.19 per share
Price / Book2.54

Profitability

EPS (Most Recent Fiscal Year)$4.36
Net Income$1.31 billion
Net Margins13.07%
Return on Equity13.35%
Return on Assets4.75%

Miscellaneous

Employees55,000
Outstanding Shares207,140,000

IQVIA (NYSE:IQV) Frequently Asked Questions

What is IQVIA's stock symbol?

IQVIA trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

How were IQVIA's earnings last quarter?

IQVIA (NYSE:IQV) issued its earnings results on Wednesday, May, 2nd. The medical research company reported $1.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.27 by $0.07. The medical research company had revenue of $2.56 billion for the quarter, compared to analysts' expectations of $2.42 billion. IQVIA had a return on equity of 13.35% and a net margin of 13.07%. The firm's quarterly revenue was up 34.1% on a year-over-year basis. View IQVIA's Earnings History.

When is IQVIA's next earnings date?

IQVIA is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for IQVIA.

What guidance has IQVIA issued on next quarter's earnings?

IQVIA updated its FY18 earnings guidance on Friday, May, 18th. The company provided EPS guidance of $5.20-5.45 for the period, compared to the Thomson Reuters consensus estimate of $5.40. The company issued revenue guidance of $10.05-10.25 billion, compared to the consensus revenue estimate of $10.15 billion.IQVIA also updated its Q2 guidance to $1.17-1.24 EPS.

What price target have analysts set for IQV?

17 brokerages have issued 12 month price objectives for IQVIA's stock. Their predictions range from $93.42 to $128.00. On average, they expect IQVIA's share price to reach $110.3776 in the next twelve months. View Analyst Ratings for IQVIA.

Who are some of IQVIA's key competitors?

Who are IQVIA's key executives?

IQVIA's management team includes the folowing people:
  • Mr. Ari Bousbib, Chairman, CEO & Pres (Age 57)
  • Mr. Michael R. McDonnell, Exec. VP & CFO (Age 54)
  • Mr. W. Richard Staub III, Pres of R&D Solutions (Age 55)
  • Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 57)
  • Mr. James H. Erlinger III, Consultant (Age 60)

Has IQVIA been receiving favorable news coverage?

Press coverage about IQV stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. IQVIA earned a coverage optimism score of 0.16 on Accern's scale. They also gave media headlines about the medical research company an impact score of 46.29 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are IQVIA's major shareholders?

IQVIA's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.63%), Farallon Capital Management LLC (1.52%), Northern Trust Corp (0.85%), Dimensional Fund Advisors LP (0.58%), Legal & General Group Plc (0.34%) and Schwab Charles Investment Management Inc. (0.28%). Company insiders that own IQVIA stock include Ari Bousbib, Corp 3I, Cpp Investment Board Private H, Dennis B Ph D Gillings, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Kevin K Gordon, Michael J Evanisko and Robert Parks. View Institutional Ownership Trends for IQVIA.

Which major investors are selling IQVIA stock?

IQV stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Sei Investments Co., Swiss National Bank, Guggenheim Capital LLC, The Manufacturers Life Insurance Company , Van ECK Associates Corp, Employees Retirement System of Texas and Northern Trust Corp. Company insiders that have sold IQVIA company stock in the last year include Ari Bousbib, Cpp Investment Board Private H, Dennis B Ph D Gillings, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko and Robert Parks. View Insider Buying and Selling for IQVIA.

Which major investors are buying IQVIA stock?

IQV stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Eagle Asset Management Inc., MD Sass Investors Services Inc., Carillon Tower Advisers Inc., Mackay Shields LLC, Farallon Capital Management LLC, Chilton Investment Co. LLC and Bloom Tree Partners LLC. View Insider Buying and Selling for IQVIA.

How do I buy shares of IQVIA?

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IQVIA's stock price today?

One share of IQV stock can currently be purchased for approximately $102.26.

How big of a company is IQVIA?

IQVIA has a market capitalization of $21.05 billion and generates $9.74 billion in revenue each year. The medical research company earns $1.31 billion in net income (profit) each year or $4.36 on an earnings per share basis. IQVIA employs 55,000 workers across the globe.

How can I contact IQVIA?

IQVIA's mailing address is 83 WOOSTER HEIGHTS ROAD, DANBURY CT, 06810. The medical research company can be reached via phone at 203-448-4600 or via email at [email protected]


MarketBeat Community Rating for IQVIA (IQV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  323 (Vote Outperform)
Underperform Votes:  282 (Vote Underperform)
Total Votes:  605
MarketBeat's community ratings are surveys of what our community members think about IQVIA and other stocks. Vote "Outperform" if you believe IQV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

IQVIA (NYSE:IQV) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
18 Wall Street analysts have issued ratings and price targets for IQVIA in the last 12 months. Their average twelve-month price target is $110.3776, suggesting that the stock has a possible upside of 7.94%. The high price target for IQV is $128.00 and the low price target for IQV is $93.42. There are currently 6 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.592.50
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $110.3776$110.3776$109.9071$102.1622
Price Target Upside: 7.94% upside14.83% upside8.21% upside1.81% downside

IQVIA (NYSE:IQV) Consensus Price Target History

Price Target History for IQVIA (NYSE:IQV)

IQVIA (NYSE:IQV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2018Goldman SachsUpgradeNeutral ➝ BuyMediumView Rating Details
4/9/2018ArgusBoost Price TargetBuy ➝ Buy$110.00 ➝ $112.00LowView Rating Details
3/7/2018SunTrust BanksUpgradeHold ➝ BuyLowView Rating Details
2/15/2018Royal Bank of CanadaSet Price TargetBuy$118.00LowView Rating Details
2/15/2018Piper Jaffray CompaniesReiterated RatingHold$103.00LowView Rating Details
2/15/2018JPMorgan ChaseBoost Price TargetOverweight$115.00 ➝ $120.00LowView Rating Details
1/24/2018MizuhoSet Price TargetHold$97.00LowView Rating Details
1/18/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$112.00HighView Rating Details
12/15/2017Mitsubishi UFJ Financial GroupInitiated CoverageNeutral$112.00LowView Rating Details
11/10/2017KeyCorpReiterated RatingOverweight ➝ Sector Weight$100.00N/AView Rating Details
11/9/2017Morgan StanleyBoost Price TargetOverweight$96.00 ➝ $121.00N/AView Rating Details
10/31/2017Credit Suisse GroupReiterated RatingOutperform$115.00 ➝ $125.00N/AView Rating Details
10/30/2017Jefferies GroupBoost Price TargetHold$107.00 ➝ $110.00N/AView Rating Details
10/27/2017BarclaysBoost Price TargetOverweight$100.00 ➝ $120.00N/AView Rating Details
10/27/2017Stifel NicolausUpgradeHold ➝ Buy$92.00 ➝ $128.00N/AView Rating Details
10/9/2017Robert W. BairdReiterated RatingHold$98.00N/AView Rating Details
8/7/2017CitigroupBoost Price TargetNeutral$96.00 ➝ $97.00LowView Rating Details
8/4/2017William BlairUpgradeMarket Perform ➝ Outperform$70.10 ➝ $93.42LowView Rating Details
2/17/2017Wells FargoUpgradeMarket Perform ➝ OutperformN/AView Rating Details
2/3/2017Deutsche BankDowngradeBuy ➝ Hold$81.00 ➝ $80.00N/AView Rating Details
12/4/2016Pacific CrestSet Price TargetBuy$82.00N/AView Rating Details
12/2/2016Bank of AmericaDowngradeBuy ➝ Neutral$89.00N/AView Rating Details
12/1/2016Raymond JamesReiterated RatingStrong-Buy ➝ Market PerformN/AView Rating Details
10/5/2016UBSReiterated RatingBuy$78.00 ➝ $90.00N/AView Rating Details
7/11/2016Avondale PartnersUpgradeMarket Perform ➝ Outperform$62.00 ➝ $87.00N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

IQVIA (NYSE:IQV) Earnings History and Estimates Chart

Earnings by Quarter for IQVIA (NYSE:IQV)

IQVIA (NYSE:IQV) Earnings Estimates

2018 EPS Consensus Estimate: $4.49
2019 EPS Consensus Estimate: $6.20
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.69$1.33$1.01
Q2 20183$0.71$1.33$1.10
Q3 20182$0.79$1.35$1.07
Q4 20183$0.94$1.54$1.31
Q1 20191$1.36$1.36$1.36
Q2 20191$1.49$1.49$1.49
Q3 20191$1.59$1.59$1.59
Q4 20191$1.76$1.76$1.76

IQVIA (NYSE IQV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2018        
5/2/2018Q1 2018$1.27$1.34$2.4210 billion$2.5630 billionViewN/AView Earnings Details
2/14/2018Q4 2017$1.34$1.32$2.1380 billion$2.1610 billionViewN/AView Earnings Details
10/26/2017Q3 2017$1.14$1.19$2.0147 billion$2.0190 billionViewN/AView Earnings Details
8/3/2017Q2 2017$1.05$1.09$1.9601 billion$1.9690 billionViewListenView Earnings Details
5/3/2017Q1 17$0.95$1.01$1.9108 billion$1.9110 billionViewListenView Earnings Details
2/14/2017Q416$1.05$1.09$1.97 billion$1.9530 billionViewListenView Earnings Details
11/2/2016Q316$0.99$1.00$1.16 billion$1.14 billionViewN/AView Earnings Details
7/27/2016Q216$0.90$0.93$1.15 billion$1.17 billionViewListenView Earnings Details
5/3/2016Q116$0.86$0.89$1.12 billion$1.11 billionViewN/AView Earnings Details
2/11/2016Q415$0.87$0.90$1.13 billion$1.13 billionViewListenView Earnings Details
10/28/2015Q315$0.81$0.94$1.11 billion$1.09 billionViewListenView Earnings Details
7/29/2015Q215$0.70$0.78$1.05 billion$1.07 billionViewListenView Earnings Details
4/29/2015Q115$0.71$0.72$1.04 billion$1.35 billionViewN/AView Earnings Details
2/12/2015Q414$0.67$0.71$1.08 billion$1.06 billionViewN/AView Earnings Details
10/30/2014Q214$0.64$0.65$1.05 billion$1.06 billionViewN/AView Earnings Details
7/31/2014Q2$0.60$0.65$1.0301 billion$1.0350 billionViewN/AView Earnings Details
5/2/2014Q114$0.55$0.68$1.02 billion$1,000.00 millionViewN/AView Earnings Details
2/19/2014Q413$0.55$0.58$980.64 million$1.38 millionViewN/AView Earnings Details
10/31/2013Q313$0.50$0.54$952.14 million$1.20 billionViewN/AView Earnings Details
8/1/2013Q2 2013$0.46$0.50$942.30 million$1.30 billionViewN/AView Earnings Details
2/15/2011$0.10$0.12ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

IQVIA (NYSE:IQV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

IQVIA (NYSE IQV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.00%
Institutional Ownership Percentage: 92.12%
Insider Trading History for IQVIA (NYSE:IQV)
Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

IQVIA (NYSE IQV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/18/2018Michael J EvaniskoDirectorSell815$100.00$81,500.00View SEC Filing  
3/15/2018Robert ParksInsiderSell896$105.73$94,734.08View SEC Filing  
3/5/2018Michael J EvaniskoDirectorSell816$100.00$81,600.00View SEC Filing  
2/26/2018James H Erlinger IIIInsiderSell10,000$100.00$1,000,000.00View SEC Filing  
1/17/2018James H Erlinger IIIInsiderSell10,000$99.97$999,700.00View SEC Filing  
12/20/2017James H Erlinger IIIInsiderSell10,000$101.21$1,012,100.00View SEC Filing  
12/1/2017Ari BousbibInsiderSell46,080$101.79$4,690,483.20View SEC Filing  
11/30/2017Cpp Investment Board Private HMajor ShareholderSell7,497,807$102.00$764,776,314.00View SEC Filing  
11/30/2017John ConnaughtonDirectorSell1,163,191$102.00$118,645,482.00View SEC Filing  
11/6/2017Jack M GreenbergDirectorSell33,400$108.07$3,609,538.00View SEC Filing  
11/1/2017Ari BousbibInsiderSell46,080$108.14$4,983,091.201,036,839View SEC Filing  
10/18/2017James H Erlinger IIIInsiderSell10,000$100.51$1,005,100.0027,340View SEC Filing  
10/2/2017Ari BousbibInsiderSell46,080$94.91$4,373,452.801,036,839View SEC Filing  
9/27/2017James H Erlinger IIIInsiderSell10,000$94.52$945,200.0027,340View SEC Filing  
9/19/2017Cpp Investment Board Private HMajor ShareholderSell6,748,026$94.87$640,185,226.62View SEC Filing  
9/19/2017John ConnaughtonDirectorSell1,030,429$94.87$97,756,799.23View SEC Filing  
9/1/2017Ari BousbibInsiderSell46,080$95.65$4,407,552.001,036,839View SEC Filing  
8/28/2017Cpp Investment Board Private HMajor ShareholderSell5,218,245$97.33$507,891,785.85View SEC Filing  
8/28/2017Dennis B Ph D GillingsDirectorSell968,023$97.33$94,217,678.599,071,839View SEC Filing  
8/25/2017Kevin C KnightlyInsiderSell19,339$99.51$1,924,423.8940,650View SEC Filing  
8/9/2017Kevin C KnightlyInsiderSell20,000$90.28$1,805,600.0046,826View SEC Filing  
8/7/2017Ari BousbibInsiderSell92,160$90.35$8,326,656.001,082,919View SEC Filing  
5/31/2017Cpp Investment Board Private HMajor ShareholderSell7,131,165$84.01$599,089,171.65View SEC Filing  
5/31/2017Dennis B Ph D GillingsDirectorSell860,000$84.01$72,248,600.0010,002,230View SEC Filing  
5/30/2017John G DanhaklDirectorSell761,143$84.01$63,943,623.43View SEC Filing  
5/17/2017Jack M GreenbergDirectorSell6,092$82.50$502,590.002,930View SEC Filing  
11/21/2016Jack M GreenbergDirectorSell2,000$79.77$159,540.002,930View SEC Filing  
6/9/2016Kevin K GordonCOOSell24,000$66.41$1,593,840.0041,899View SEC Filing  
6/7/2016Corp 3IMajor ShareholderSell2,250,000$66.10$148,725,000.00View SEC Filing  
5/12/2016Annie H LoDirectorBuy502$64.80$32,529.602,062View SEC Filing  
5/10/2016Kevin K GordonCOOSell24,000$67.42$1,618,080.0041,899View SEC Filing  
4/12/2016Kevin K GordonCOOSell24,000$69.44$1,666,560.0041,899View SEC Filing  
3/22/2016Kevin K GordonCOOSell3,639$65.01$236,571.3921,538View SEC Filing  
3/18/2016Kevin K GordonCOOSell20,361$65.01$1,323,668.6119,950View SEC Filing  
3/1/2016Kevin K. GordonCOOSell24,000$65.03$1,560,720.0041,899View SEC Filing  
9/2/2015Charles Edward WilliamsSVPSell5,000$72.43$362,150.002,071View SEC Filing  
5/19/2015Dennis B Ph D GillingsMajor ShareholderSell2,503,123$64.85$162,327,526.55View SEC Filing  
5/19/2015Tpg Advisors V, Inc.InsiderSell2,251,719$64.85$146,023,977.15View SEC Filing  
3/25/2015Michael J EvaniskoDirectorSell2,500$67.10$167,750.00View SEC Filing  
2/2/2015Kevin K GordonCFOSell25,000$60.19$1,504,750.00View SEC Filing  
1/7/2015Michael J EvaniskoDirectorSell2,500$57.86$144,650.00View SEC Filing  
1/2/2015Kevin K GordonCFOSell25,000$59.16$1,479,000.00View SEC Filing  
12/11/2014Jack M GreenbergDirectorSell23,508$57.29$1,346,773.32View SEC Filing  
12/1/2014Kevin K GordonCFOSell25,000$56.77$1,419,250.00View SEC Filing  
11/10/2014Dennis B Ph D GillingsMajor ShareholderSell3,566,187$58.09$207,159,802.83View SEC Filing  
11/7/2014Michael J EvaniskoDirectorSell2,500$57.50$143,750.00View SEC Filing  
11/3/2014Kevin K GordonCFOSell25,000$59.00$1,475,000.00View SEC Filing  
7/2/2014Michael J EvaniskoDirectorSell5,000$54.00$270,000.00View SEC Filing  
5/27/2014Tpg Advisors Iii, Inc.Major ShareholderSell3,287,209$50.23$165,116,508.07View SEC Filing  
3/26/2014Christopher GordonDirectorSell570,682$50.31$28,711,011.42View SEC Filing  
3/26/2014Dennis Ph Gillingsmajor shareholderSell570,681$50.31$28,710,961.1116,609,827View SEC Filing  
3/18/2014Mireille Phd GillingsDirectorSell3,304,542$50.31$166,251,508.02View SEC Filing  
3/18/2014Tpg Advisors Iii, Inc.major shareholderSell3,564,119$50.31$179,310,826.89View SEC Filing  
1/17/2014Derek WinstanlyVPSell60,000$50.00$3,000,000.00229,500View SEC Filing  
1/16/2014Michael EvaniskoDirectorSell5,000$50.00$250,000.0015,400View SEC Filing  
1/10/2014Derek WinstanlyVPSell60,000$48.00$2,880,000.00229,500View SEC Filing  
12/20/2013Derek WinstanlyVPSell60,000$46.00$2,760,000.00229,500View SEC Filing  
12/10/2013Derek WinstanlyVPSell60,000$44.00$2,640,000.00229,500View SEC Filing  
11/20/2013Michael EvaniskoDirectorSell8,000$43.00$344,000.0020,400View SEC Filing  
11/18/2013John RatliffCOOSell212,140$42.55$9,026,557.00View SEC Filing  
11/18/2013Michael MortimerVPSell200,000$42.55$8,510,000.0025,000View SEC Filing  
5/14/2013Group Holdings (Sbs) Advis TpgMajor ShareholderSell3,944,899$37.80$149,117,182.20View SEC Filing  
5/14/2013Mireille GillingsDirectorSell2,257,805$37.80$85,345,029.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

IQVIA (NYSE IQV) News Headlines

Source:
DateHeadline
 Analysts Expect IQVIA (IQV) Will Post Quarterly Sales of $2.46 Billion Analysts Expect IQVIA (IQV) Will Post Quarterly Sales of $2.46 Billion
www.americanbankingnews.com - May 21 at 4:00 AM
IQVIA (IQV) Expected to Announce Earnings of $1.25 Per ShareIQVIA (IQV) Expected to Announce Earnings of $1.25 Per Share
www.americanbankingnews.com - May 19 at 1:07 PM
IQVIA Reaffirms Its Second-Quarter and Full-Year 2018 Guidance, Including Adjusted EPS Growth of 13.6% to 20.4 ...IQVIA Reaffirms Its Second-Quarter and Full-Year 2018 Guidance, Including Adjusted EPS Growth of 13.6% to 20.4 ...
www.businesswire.com - May 18 at 9:48 AM
BRIEF-Iqvia Holdings Provides Update On Secondary OfferingBRIEF-Iqvia Holdings Provides Update On Secondary Offering
www.reuters.com - May 18 at 9:48 AM
BRIEF-IQVIA Reaffirms Its Second-Quarter and FY 2018 GuidanceBRIEF-IQVIA Reaffirms Its Second-Quarter and FY 2018 Guidance
www.reuters.com - May 18 at 9:48 AM
PruGen Pharmaceuticals Selects IQVIAs OCE Technology Platform to Advance Field Sales and Home Office ...PruGen Pharmaceuticals Selects IQVIA's OCE Technology Platform to Advance Field Sales and Home Office ...
www.businesswire.com - May 18 at 9:48 AM
IQVIA Holdings (IQV) Secures Technology Platform Contract from PruGen Pharmaceuticals for Advanced Field Sales ...IQVIA Holdings (IQV) Secures Technology Platform Contract from PruGen Pharmaceuticals for Advanced Field Sales ...
www.streetinsider.com - May 18 at 9:48 AM
IQVIA (IQV) Issues FY18 Earnings GuidanceIQVIA (IQV) Issues FY18 Earnings Guidance
www.americanbankingnews.com - May 18 at 8:58 AM
IQVIA (IQV) Updates Q2 Earnings GuidanceIQVIA (IQV) Updates Q2 Earnings Guidance
www.americanbankingnews.com - May 18 at 8:58 AM
IQVIA reaffirms Q2 and FY guidanceIQVIA reaffirms Q2 and FY guidance
seekingalpha.com - May 18 at 7:34 AM
IQVIA Holdings (IQV) call put ratio 1 call to 10.8 puts with focus on May 95 and 97.50 puts into trading haltIQVIA Holdings (IQV) call put ratio 1 call to 10.8 puts with focus on May 95 and 97.50 puts into trading halt
www.streetinsider.com - May 16 at 4:45 PM
Brainstorm Health: Teen Suicide Attempt Spike, IQVIA Accuracy, Novartis Cohen FalloutBrainstorm Health: Teen Suicide Attempt Spike, IQVIA Accuracy, Novartis Cohen Fallout
fortune.com - May 16 at 4:45 PM
BRIEF-FDA Reports Quality Problems For Data Provided By IQVIA That Were Used To Inform Estimates For Some ...BRIEF-FDA Reports Quality Problems For Data Provided By IQVIA That Were Used To Inform Estimates For Some ...
www.reuters.com - May 16 at 4:45 PM
BRIEF-IQVIA Responds To FDA Statement Regarding Conversion Measurement IssueBRIEF-IQVIA Responds To FDA Statement Regarding Conversion Measurement Issue
www.reuters.com - May 16 at 4:45 PM
Iqvia stock drops after FDA questions sales dataIqvia stock drops after FDA questions sales data
finance.yahoo.com - May 16 at 4:45 PM
FDA reports inaccuracy in IQVIA data on opioidsFDA reports inaccuracy in IQVIA data on opioids
finance.yahoo.com - May 16 at 4:45 PM
Form FWP IQVIA HOLDINGS INC. Filed by: IQVIA HOLDINGS INC.Form FWP IQVIA HOLDINGS INC. Filed by: IQVIA HOLDINGS INC.
www.streetinsider.com - May 16 at 9:24 AM
Head-To-Head Contrast: IQVIA (IQV) & National Research (NRCIA)Head-To-Head Contrast: IQVIA (IQV) & National Research (NRCIA)
www.americanbankingnews.com - May 15 at 5:19 AM
IQVIA (IQV) Receives Consensus Recommendation of "Buy" from BrokeragesIQVIA (IQV) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 13 at 5:31 PM
Head-To-Head Analysis: Anavex Life Sciences (AVXL) & IQVIA (IQV)Head-To-Head Analysis: Anavex Life Sciences (AVXL) & IQVIA (IQV)
www.americanbankingnews.com - May 10 at 11:19 PM
IQVIA to Present at the Bank of America Merrill Lynch Health Care Conference on May 15, 2018IQVIA to Present at the Bank of America Merrill Lynch Health Care Conference on May 15, 2018
finance.yahoo.com - May 8 at 4:43 PM
Form 10-Q IQVIA HOLDINGS INC. For: Mar 31Form 10-Q IQVIA HOLDINGS INC. For: Mar 31
www.streetinsider.com - May 4 at 9:07 AM
IQVIA (IQV) Upgraded by ValuEngine to BuyIQVIA (IQV) Upgraded by ValuEngine to Buy
www.americanbankingnews.com - May 4 at 12:17 AM
IQVIA Holdings Delivers on Its PromisesIQVIA Holdings Delivers on Its Promises
finance.yahoo.com - May 3 at 4:38 PM
Edited Transcript of IQV.N earnings conference call or presentation 2-May-18 1:00pm GMTEdited Transcript of IQV.N earnings conference call or presentation 2-May-18 1:00pm GMT
finance.yahoo.com - May 3 at 9:05 AM
IQVIA (IQV) Expected to Post Quarterly Sales of $2.44 BillionIQVIA (IQV) Expected to Post Quarterly Sales of $2.44 Billion
www.americanbankingnews.com - May 3 at 2:10 AM
IQVIA Holdings (IQV) CEO Ari Bousbib on Q1 2018 Results - Earnings Call TranscriptIQVIA Holdings' (IQV) CEO Ari Bousbib on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 2 at 4:46 PM
IQVIA (IQV) Announces Quarterly  Earnings ResultsIQVIA (IQV) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 2 at 1:40 PM
IQVIA (IQV) Updates FY18 Earnings GuidanceIQVIA (IQV) Updates FY18 Earnings Guidance
www.americanbankingnews.com - May 2 at 9:33 AM
BRIEF-Iqvia Holdings Q1 GAAP Earnings Per Share $0.32BRIEF-Iqvia Holdings Q1 GAAP Earnings Per Share $0.32
www.reuters.com - May 2 at 9:09 AM
IQVIA: 1Q Earnings SnapshotIQVIA: 1Q Earnings Snapshot
finance.yahoo.com - May 2 at 9:09 AM
Zacks: Analysts Expect IQVIA (IQV) to Announce $1.28 EPSZacks: Analysts Expect IQVIA (IQV) to Announce $1.28 EPS
www.americanbankingnews.com - May 1 at 9:14 PM
Iqvia files suit over payroll outsourcing that impacts more than 13000 employeesIqvia files suit over payroll outsourcing that impacts more than 13000 employees
www.bizjournals.com - April 30 at 4:38 PM
Recordati Selects IQVIAs OCE Technology Platform and OneKey Information ServicesRecordati Selects IQVIA's OCE Technology Platform and OneKey Information Services
www.businesswire.com - April 30 at 9:19 AM
Iqvia files suit over payroll outsourcing that impacts more than 13,000 employeesIqvia files suit over payroll outsourcing that impacts more than 13,000 employees
finance.yahoo.com - April 30 at 9:19 AM
Iqvia (IQV) Set to Announce Earnings on WednesdayIqvia (IQV) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - April 25 at 8:58 AM
EARNINGS: Philip Morris misses on revenue, selling fewer cigarettes in Saudi ArabiaEARNINGS: Philip Morris misses on revenue, selling fewer cigarettes in Saudi Arabia
finance.yahoo.com - April 21 at 4:41 PM
Insider Selling: Iqvia Holdings Inc (IQV) Director Sells 815 Shares of StockInsider Selling: Iqvia Holdings Inc (IQV) Director Sells 815 Shares of Stock
www.americanbankingnews.com - April 20 at 7:40 PM
Prescriptions of the drugs that fueled the overdose crisis are dropping around the USPrescriptions of the drugs that fueled the overdose crisis are dropping around the US
www.businessinsider.com - April 19 at 9:09 AM
IQVIA™ Institute for Human Data Science Study: U.S. Prescription Opioid Volume Declined 12 Percent in 2017 – Largest Drop in 25 YearsIQVIA™ Institute for Human Data Science Study: U.S. Prescription Opioid Volume Declined 12 Percent in 2017 – Largest Drop in 25 Years
finance.yahoo.com - April 19 at 9:09 AM
Iqvia Holdings Inc (IQV) Given Average Rating of "Buy" by AnalystsIqvia Holdings Inc (IQV) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 18 at 5:17 PM
IQVIA to Announce First-Quarter 2018 Results on May 2, 2018IQVIA to Announce First-Quarter 2018 Results on May 2, 2018
finance.yahoo.com - April 18 at 4:56 PM
Iqvia (IQV) Upgraded at Zacks Investment ResearchIqvia (IQV) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 18 at 7:46 AM
$2.44 Billion in Sales Expected for Iqvia Holdings Inc (IQV) This Quarter$2.44 Billion in Sales Expected for Iqvia Holdings Inc (IQV) This Quarter
www.americanbankingnews.com - April 16 at 1:56 AM
Zacks: Analysts Expect Iqvia Holdings Inc (IQV) to Post $1.28 EPSZacks: Analysts Expect Iqvia Holdings Inc (IQV) to Post $1.28 EPS
www.americanbankingnews.com - April 14 at 11:20 PM
Reviewing EXACT Sciences (EXAS) and Iqvia (IQV)Reviewing EXACT Sciences (EXAS) and Iqvia (IQV)
www.americanbankingnews.com - April 14 at 5:27 PM
Goldman likes CRO space, sees 17% upside in IQVIA; shares up 2%Goldman likes CRO space, sees 17% upside in IQVIA; shares up 2%
seekingalpha.com - April 13 at 4:43 PM
Goldman Sachs Upgrades Iqvia (IQV) to "Buy"Goldman Sachs Upgrades Iqvia (IQV) to "Buy"
www.americanbankingnews.com - April 13 at 10:37 AM
Financial Review: Iqvia (IQV) & Exelixis (EXEL)Financial Review: Iqvia (IQV) & Exelixis (EXEL)
www.americanbankingnews.com - April 12 at 5:27 PM
Dennis Gillings retires from Iqvias board of directorsDennis Gillings retires from Iqvia's board of directors
www.bizjournals.com - April 12 at 4:43 PM

SEC Filings

IQVIA (NYSE:IQV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

IQVIA (NYSE:IQV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

IQVIA (NYSE IQV) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.